pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›EFINACONAZOLE
drug
save

EFINACONAZOLE

Marketedupdated 3mo ago
by Ortho Dermatologics Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 1
  • tagApproval2 co-mentions · 1 sources

all catalysts(1)

approval · 1
Feb 23, 2026
approval
6mo ago
EFINACONAZOLE — FDA approval
EFINACONAZOLE
→

Trials studying EFINACONAZOLE

  • phase2A Phase 2 Study to Assess the Effectiveness of Topical Terbinafine in Participants With Mild to Moderate Onychomycosis of the Toenailsnot yet recruitingn=200

Patent cliff

source: FDA Orange Book
first barrier falls
Jan 3, 2028
~1.4 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (18)

  • Apr 25, 2035formulationUS 10478601
  • Oct 2, 2034formulationUS 10342875
  • Oct 2, 2034method-of-use (U-2720)US 10828293
  • Oct 2, 2034method-of-use (U-2720)US 10864274
  • Oct 2, 2034method-of-use (U-1969)US 11654139
  • Oct 2, 2034formulationUS 9662394
  • Oct 24, 2030formulationUS 84869784.2y
  • Oct 24, 2030formulationUS 93020094.2y
  • Jul 8, 2030formulationUS 101054443.9y
  • Jul 8, 2030method-of-use (U-281)US 80394943.9y
  • Jul 8, 2030formulationUS 98616983.9y
  • Jan 3, 2028method-of-use (U-1969)US 105126401.4y
  • Jan 3, 2028formulationUS 108283691.4y
  • Jan 3, 2028method-of-use (U-2720)US 112135191.4y
  • Jan 3, 2028method-of-use (U-1969)US 118722181.4y
  • Jan 3, 2028method-of-use (U-1969)US 95662721.4y
  • Jan 3, 2028method-of-use (U-1969)US 98779551.4y
  • Feb 22, 2026method-of-use (U-281)US 7214506

News(0)

no news has mentioned this drug yet

brand
EFINACONAZOLE
generic
EFINACONAZOLE
indication
Onychomycosis (Tinea Unguium)
phase
marketed
Data sources
openFDA · ClinicalTrials.gov
last refreshed 7m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?